| pubmed-article:9256894 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C0007138 | lld:lifeskim |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C0600139 | lld:lifeskim |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C0026259 | lld:lifeskim |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C0085973 | lld:lifeskim |
| pubmed-article:9256894 | lifeskim:mentions | umls-concept:C0007320 | lld:lifeskim |
| pubmed-article:9256894 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9256894 | pubmed:dateCreated | 1997-9-4 | lld:pubmed |
| pubmed-article:9256894 | pubmed:abstractText | A 61-year-old man with pulmonary and bone metastases from a primary transitional cell carcinoma of the prostate (TCCP) refractory to MVAC was treated with mitoxantrone 16 mg/m2 i.v. at 3-week intervals. With this, he experienced an objective partial remission lasting 5 months and a significant decrease in cancer-related symptoms. Mitoxantrone deserves further evaluation in this rare disease. | lld:pubmed |
| pubmed-article:9256894 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9256894 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9256894 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9256894 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9256894 | pubmed:issn | 0277-3732 | lld:pubmed |
| pubmed-article:9256894 | pubmed:author | pubmed-author:StewartD JDJ | lld:pubmed |
| pubmed-article:9256894 | pubmed:author | pubmed-author:DahrougeSS | lld:pubmed |
| pubmed-article:9256894 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9256894 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:9256894 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9256894 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9256894 | pubmed:pagination | 381-2 | lld:pubmed |
| pubmed-article:9256894 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:meshHeading | pubmed-meshheading:9256894-... | lld:pubmed |
| pubmed-article:9256894 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9256894 | pubmed:articleTitle | Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report. | lld:pubmed |
| pubmed-article:9256894 | pubmed:affiliation | Ontario Cancer Treatment and Research Foundation, Canada. | lld:pubmed |
| pubmed-article:9256894 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9256894 | pubmed:publicationType | Case Reports | lld:pubmed |
